Ehud Geller

Collgard Biopharmaceuticals, the tissue therapeutics company, is developing drug treatments that target disease progression by directly influencing the tissue regeneration process. Central to Collgard's novel approach is its lead drug candidate, Tempostatin (Halofuginone hydrobromide). Tempostatin is a multi-indication, small-molecule drug candidate that has been identified by the company as influencing a 'master switch' in the body's tissue repair process. As a potent and selective regulator of stromal cell activation, cell migration and excessive collagen type I synthesis, Tempostatin makes it possible to harness and direct the tissue repair process for treating diseases acting at the tissue level. Collgard is developing therapeutic solutions for several clinical indications with significant unmet clinical needs. These solutions are based on highly specific control of the tissue repair process. Current programs target the following indications vascular restenosis, end-organ fibrosis, selected cancers and dermal fibroproliferative disorders. Tempostatin holds exceptional promise based on addressing a fundamental underlying pathological process that is not accessible to other current therapeutic approaches. In developing Tempostatin, Collgard seeks to offer novel therapeutic solutions as well as extend the effectiveness of existing therapies. Founded in 1996, Collgard Biopharmaceuticals is a privately held, clinical stage company, led by a global team of medical and drug development experts based in Atlanta and Tel Aviv. Scientific and clinical collaborators include The Mayo Clinic, the U.S. NCI, the EORTC, and Harvard Medical School. Collgard was founded by Medica Venture Partners. Additional investors include Mayo Medical Ventures, Denali Ventures, Yozma Group, and Comsor.

Part of Merck KGaA, Interpharm Laboratories Ltd. is an Israeli company that develops recombinant cytokines for the treatment of viral infections, cancer and autoimmune diseases. The private company is based in Rehovot, Israel. The company was founded by Israel Makov.

Vidyatel Ltd. was engaged in the development of video-based content monitoring system. The company was founded in 2002 and was headquartered in Jerusalem, Israel.

Regentis Biomaterials Ltd. engages in the research and development of proprietary hydrogels for local repair of damaged cartilage and bone. Its product is GelrinC. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

Gardia Medical specializes in the development of catheter-based delivery systems that easily integrate with the standard workflow of stenting and other cardiovascular intervention procedures. It offers wire-independent distal filtration Embolic Protection Device (EPD), compatible with standard guide wires. The company was founded by Benjamin Spenser and Uri Rosenshein in 2006 and is headquartered in Hadera, Israel.

Part of The Tel Aviv Stock Exchange Ltd., The Tel Aviv Stock Exchange (Investment Management) is a private company that provides fund management services. The company is based in Tel Aviv, Israel. Ittai Ben Zeev has been the CEO of the Israeli company since 2017.